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AbstrACt
Introduction Contraceptive use among HIV-infected 
women in Togo is poorly documented. We aim at 
assessing the prevalence of modern contraceptive use and 
associated factors among HIV-infected women in Togo.
Design Cross-sectional study.
setting The study was conducted in five HIV care centres 
in the Centrale and Kara regions in Togo.
Participants We included 461 HIV-positive women aged 
between 15 and 49 years and who were sexually active.
Main outcome measure The outcome variable was HIV-
infected women who were using modern contraceptive 
methods.
results A total of 461 HIV-infected women were 
interviewed, with an average age of 34.3 (±7.1). Among 
them, 332 (73.1%) women reported using contraceptive 
methods, mostly condom alone (74.7%) or in combination 
with hormonal contraceptive (16.9%). In multivariate 
analysis, education level (primary: adjusted OR 
(aOR)=1.99, 95% CI (1.05 to 3.76); secondary level and 
higher: aOR=3.95, 95% CI (2.03 to 7.67)), WHO clinical 
stage (stage II: aOR=0.7, 95% CI (0.37 to 1.33)), follow-up 
in private care facilities (aOR=2.54, 95% CI (1.22 to 5.29)) 
and having a child (aOR=2.51, 95% CI (1.41 to 4.5)) were 
associated with higher contraceptive use, while marital 
status (living in union: aOR=0.45, 95% CI (0.28 to 0.74)) 
and WHO stages III and IV (aOR=0.47, 95% CI (0.24 to 
0.94)) were associated with lower contraceptive use.
Conclusion About three-quarters of sexually active 
HIV-infected women in Togo were using contraceptive 
methods, and private health facilities favoured this 
contraceptive use. It is important to strengthen the 
implementation of interventions to increase the incentives 
for HIV-infected women to use contraception in Togo.
bACkgrounD 
Although there has been a reduction in new 
infections of HIV of about 41% between 
2000 and 2015, HIV infection continues to 
be a public health problem in Sub-Saharan 
Africa, where 25.6 million people lived with 
HIV. Women of reproductive age account 
for about two-thirds of them.1 The decline in 
the incidence of HIV infection is the effect 
of multiple interventions implemented to 
prevent HIV transmission among hetero-
sexual and especially from mother-to-child 
HIV transmission. About 66 000 children 
under 14 years were reported to be newly 
infected by HIV in Western and Central Africa 
at the end of 2015.2 Most of these infections 
could have been prevented by antiretroviral 
therapy (ART) during pregnancy and more 
by contraceptive use among HIV-infected 
women, which is the fourth component of 
preventing mother-to-child transmission 
(PMTCT). In 2005, Reynolds et al3 estimated 
that the level of contraceptive use could 
prevent over 173 000 unintended HIV-in-
fected births each year in Sub-Saharan Africa.
Indeed, family planning showed numerous 
benefits for HIV-infected women, such as the 
reduction of morbidity and mortality due 
to pregnancy and also the improvement of 
health of HIV-infected women by reducing 
unintended pregnancies. Therefore family 
planning contributes to PMTCT of HIV.4 The 
strengths and limitations of this study
 ► The use of contraceptives such as condoms could 
provide dual protection against acquisition or trans-
mission of sexually transmitted infections, including 
HIV.
 ► This study is one of the first studies in Togo focus-
ing its interest on the contraceptive use among HIV-
positive women.
 ► Education level, marital status, AIDS clinical stage, 
type of health centre and having children had influ-
enced the use of contraceptive methods among HIV-
infected women.
 ► It is suggested that caregivers should integrate fam-
ily planning services in HIV care during follow-up 
visits.
 ► Finally, we relied on self-reported reproductive 
health behaviour through a face-to-face interview, 
which may introduce information bias.
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use of contraceptives, mainly male and female condoms, 
could provide dual protection. It could protect against 
acquisition or transmission of sexually transmitted infec-
tions, including HIV.5 6 However, in Sub-Saharan Africa, 
given the progress in PMTCT with the expansion of ART, 
most of the HIV-infected women still have desire to have 
children,7 8 and the prevalence of contraceptive use varies 
according to the studies. In Western Africa, the use of 
contraceptive methods is not effective in HIV-infected 
women.9–11 In Ghana, a study showed that only 42.6% of 
HIV-infected women used modern contraceptive methods 
at Komfo Anokye Teaching Hospital in 2012,11 while in 
eastern Nigeria it was reported that 73.1% of HIV-in-
fected women were using modern contraceptives in the 
same period.10 In many studies conducted in Sub-Saharan 
Africa, the reported factors influencing the use of contra-
ceptive among HIV-positive women were sociodemo-
graphic characteristics (age, education, marital status), 
reproductive characteristics (desire to have children, 
number of children), being on ART and knowledge of 
the partner’s HIV status.9–14
In 2015, Togo had about 110 000 people living with HIV 
and AIDS (PLWHA), including 59 000 women aged more 
than 15 years old and 9000 children aged 0–14 years.15 In 
addition, the prevalence of HIV infection is almost twice 
higher among women than men (3.1% vs 1.7%).16 HIV 
prevalence among women attending antenatal consulta-
tion in Togo was 2% in 2015.17 In women of reproductive 
age, the prevalence of contraceptive use was estimated at 
22% for all methods (16% for modern methods) in 2013–
2014.16 However, contraceptive use among HIV-infected 
women in Togo is poorly documented.
This study aims at assessing the prevalence of contra-
ceptive use, as well as individual and structural factors 
that influenced the use of contraceptives among HIV-in-
fected women enrolled in HIV care centres in two health 
regions in Togo.
MethoDs
study design
This was a cross-sectional study conducted in two health 
regions in Togo (Centrale and Kara regions) over a 
period of 4 months from May to August 2016. The study 
targeted HIV-positive women of reproductive age (15–49 
years) and who were sexually active.
setting and study population
Centrale and Kara regions are two of the six health regions 
in Togo located, respectively, about 350 km and 420 km 
from the capital Lomé. These two regions are character-
ised by important seasonal arrival of populations (from 
the other health regions, and sometimes from outside 
of the country (Togo)) during cultural and traditional 
events, increasing the risks of HIV transmission. In 2013, 
the prevalence of HIV infection was estimated at 2.2% in 
the Centrale region and 1.8% in the Kara region.16 There 
were 30 accredited medical centres in the two regions to 
provide healthcare to about 10 361 PLWHA, including 
616 children, enrolled and followed up in these centres.17
Women were eligible to participate in the study if they 
(1) were aged between 15 and 49 years old, (2) had a 
sexual partner within the last 6 months and (3) were 
enrolled in the selected centres for active ART.
sampling
First, a random probability sampling proportional to 
the number of patients in the active file of the 30 HIV 
care centres in the two regions was carried out to ensure 
representative centres with a high number of PLWHA. 
In a minimalist scenario, it is assumed that a sample of 
15% of HIV care centres should be representative of all 
the centres. This led to the random selection of five HIV 
care centres for the implementation of this study. Then, 
a non-probabilistic, convenience sampling was carried 
out. Indeed, in these five selected HIV care centres, it 
was proposed to enrol any PLWHA who consulted for a 
follow-up from May to August 2016, who met the inclu-
sion criteria and who consented to participate in the 
study. The prevalence of the use of at least one contracep-
tive method was assumed to be 50% with the precision of 
5% and 20% refusal or incomplete data. Based on this 
assumption, the sample size was estimated at 461 HIV-in-
fected women.
Data collection
Data collection was done using a standardised question-
naire in French, explained in the local language for 
participants if needed. The questionnaires were filled by 
the health workers. The questionnaire included sociode-
mographic information, clinical features, information on 
ART, sexual activity status, and knowledge on contracep-
tives and their use. Data on HIV status disclosure to the 
sexual partner were also collected among PLWHA. We 
defined modern contraception as the use of one of the 
following methods: sterilisation, condoms, contraceptive 
pill/oral contraceptives, intrauterine device, diaphragm, 
injection, emergency contraception or implant.
statistical analysis of data
Data entry was performed using EpiData V.3.1 software. 
Data were then exported for statistical analyses using 
SPSS V.17.0.
For continuous variables, mean and SD were calculated, 
while for categorical variables we calculated the propor-
tions. Our main outcome variable was HIV-infected 
women who were currently using any modern contra-
ceptive methods. Pearson’s χ2 test or Fisher’s exact test 
was used when appropriate in bivariate analysis. Multi-
variate backwards stepwise logistic regression analysis 
was performed to identify independent risk factors for 
the dichotomous outcome contraceptive use or not. All 
variables significant during bivariate analysis at a p value 
<0.20 were introduced in a logistic regression model to 
estimate the adjusted OR (aOR). Interactions between 
the independent variables were tested. All these analyses 
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were performed with 95% CI. To verify the robustness of 
the results, a sensitivity analysis was conducted to confirm 
the results found. We have performed the analysis by 
including women who have never heard about contracep-
tive methods, and then we excluded them to appreciate 
the variability of the statistical associations. We did not 
observe significant variability and logically we excluded 
those women (15/461) from the model. Our final model 
included only HIV-infected women who had heard about 
contraceptives methods.
ethical issues
We obtained consent from patients who participated in 
the study. For each of the person surveyed, the objectives, 
benefits to participate in the survey and progress of the 
investigation were clearly stated, as well as their right to 
interrupt the interview without justification. An informed 
consent form signed after the verbal explanation was 
made by the investigating officer in the language under-
stood by the participant.
results
sociodemographic and clinical characteristics
Table 1 shows the sociodemographic and clinical char-
acteristics of the participants. In total 461 HIV-infected 
women of reproductive age and who were sexually active 
were enrolled into this study, of whom 267 (57.9%) were 
in the Centrale region and 194 (42.1%) in the Kara 
region. The mean (±SD) age of the participants was 
34.3±7.1 years, ranging from 16 to 49 years. Among them, 
40.6% had primary education or higher education level 
(45.3%), 54.7% were living in couple and 62.3% were 
living in an urban area. Out of the 461 women inter-
viewed, 415 (90.0%) were on ART and for more than 
2 years for 71% of them. The mean (±SD) duration on 
ART was 4.1±2.8 years. A quarter (25.4%) of the partic-
ipants had a CD4 cell count of <0.35 × 109/L at the last 
visit. Patients were classified as stage I (55.0%) or stage II 
(27.3%) based on the WHO clinical classification at the 
time of the survey. The partner’s HIV status was unknown 
for 56.4% (260/461) of the participants. Most of the 
patients were followed up in a public hospital centre 
(61.8%), in a centre with available doctor (86.3%) or with 
a psychologist (55.7%).
reproductive health outcome
The majority of women (85.3%) reported having at least 
one child, while six out of ten participants expressed 
desire of having kids. Four hundred and forty six (96.7%) 
women reported that they heard about contraceptives 
methods. Among them, 70.2% (313/446) were informed 
by healthcare providers. At the time of the survey, the 
proportion of women who were using a contraceptive 
method was 74.7% (333/446) (table 1), and among them 
74.5% (248/333) reported using condom, 8.4% (28/333) 
were using hormonal contraceptive and 16.9% (56/333) 
reported using dual methods combining condom and 
hormonal contraceptive. For 15 (3.3%) women who have 
never heard about contraceptives methods, we consid-
ered they had missing data for the variable contraceptive 
use.
Furthermore the proportion of women using contra-
ceptive was significantly higher among participants 
with higher level of education, ranging from 57.1% 
in women with no education to 82.8% in those having 
reached the secondary education level or higher 
(p<0.001). However, this proportion was significantly 
higher (p<0.001) among women at stage I (82.1%) than 
those at stage II (70.0%) or those at stages III and IV 
(58.4%). The prevalence of contraceptive use was signifi-
cantly lower in women living in couple (p=0.002), higher 
among those who had children (p=0.032) and higher in 
women on ART for 2 years or more (p=0.025). Women 
followed up in a private centre (p<0.001) or a centre with 
a psychologist (p=0.011) were more susceptible to use 
contraceptive methods (table 1).
Factors associated with contraceptive use
In multivariate analysis, only five factors remained asso-
ciated with contraceptive use: education level, marital 
status, clinical stage, type of health centre and having 
children. Women with primary education level or those 
with secondary education level or higher were, respec-
tively, two times more likely (aOR=1.99, 95% CI (1.05 
to 3.76)) and four times more likely (aOR=3.95, 95% CI 
(2.03 to 7.67)) to use a contraceptive method than those 
who did not have any education, whereas participants 
living in couple were 55% less likely (aOR=0.45, 95% CI 
(0.28 to 0.74)) to use a contraceptive method. Women 
who reported having children and those followed up 
in a private structure were almost three times more 
likely (respectively, aOR=2.51, 95% CI (1.41 to 4.5) and 
aOR=2.54, 95% CI (1.22 to 5.29)) to report current use 
of contraceptive. Patients at AIDS clinical stage III or IV 
were 53% less likely (aOR=0.47, 95% CI (0.23 to 0.87)) to 
use a contraceptive method than those at clinical stage I. 
In addition this likelihood of using contraceptive is even 
lower for HIV-infected women at AIDS clinical stage III 
or IV followed up in private centres (aOR=0.13, 95% CI 
(0.03 to 0.64)) (table 2).
DIsCussIon
In this study, conducted in two regions in north of Togo, 
96.7% of HIV-infected women had heard about contra-
ceptive methods and mainly from health providers. 
Education level, marital status, AIDS clinical stage, type of 
health centre and having children had influenced the use 
of contraceptive methods among HIV-infected women.
A high proportion of knowledge on contraceptive 
methods was also reported among women aged 15–49 
years in the general population in Togo (96.3%) in 
2013–201416 and among HIV-infected women on ART 
in Ethiopia (97.0%) in 2013.18 This showed that sero-
positive women were as exposed to reproductive health 
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Table 1 Characteristics of HIV-infected women in the study population (n=461)
n (%)
Contraceptive use
P valuesNo, n (%) Yes, n (%)
Age 0.694
  <25 years 40 (8.7) 8 (20.5) 31 (79.5)
  25–34 years 193 (41.9) 46 (24.7) 140 (75.3)
  35–49 years 228 (49.5) 59 (26.7) 162 (73.3)
Education level <0.001
  No education 65 (14.1) 27 (42.9) 36 (57.1)
  Primary 187 (40.6) 51 (28.5) 128 (71.5)
  Secondary and higher 209 (45.3) 35 (17.2) 169 (82.8)
Profession of participants .192
  Public sector 34 (7.4) 7 (20.6) 27 (79.4)
  Private sector 20 (4.3) 4 (20.0) 16 (80.0)
  Informal sector 234 (50.8) 68 (29.7) 160 (70.3)
  No profession 173 (37.5) 34 (20.9) 129 (79.1)
Marital status 0.003
  In couple 252 (54.7) 75 (30.9) 168 (69.1)
  Single 209 (45.3) 38 (18.7) 165 (81.3)
Residence of patients 0.965
  Urban 287 (62.3) 71 (25.3) 210 (74.7)
  Rural 174 (37.7) 42 (25.5) 123 (74.5)
Region 0.065
  Centrale 267 (57.9) 73 (28.6) 182 (71.4)
  Kara 194 (42.1) 40 (20.9) 151 (79.1)
Religion 0.061
  None 41 (8.9) 11 (26.8) 30 (73.2)
  Islam 155 (33.6) 48 (31.8) 103 (68.2)
  Christianism 265 (57.5) 54 (21.3) 200 (78.7)
WHO clinical stage <0.001
  Stage I 252 (55.0) 44 (17.9) 202 (82.1)
  Stage II 125 (27.3) 36 (30.0) 84 (70.0)
  Stages III and IV 81 (17.6) 32 (41.6) 45 (58.4)
Symptom intensity 0.018
  None 197 (42.7) 53 (27.6) 139 (72.4)
  Moderate 242 (52.5) 51 (21.6) 185 (78.4)
  Severe 22 (4.8) 9 (50.0) 9 (50.0)
CD4 cell counts  0.876
  <0.35 × 109/L 117 (25.4) 29 (25.9) 83 (74.1)
  ≥ 0.35 × 109/L 344 (74.6) 84 (25.1) 250 (74.9)
ART 0.756
  Yes 415 (90.0) 101 (25.1) 301 (74.9)
  No 46 (10.0) 12 (27.3) 32 (72.7)
ART scheme (n=415) 0.168
  First line 382 (92.0) 96 (26.0) 273 (74.0)
  Second line 33 (8.0) 5 (15.2) 28 (84.8)
ART duration (=414) 0.025
  <2 years 120 (29.0) 38 (32.8) 78 (67.2)
Continued
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n (%)
Contraceptive use
P valuesNo, n (%) Yes, n (%)
  ≥2 years 294 (71.0) 63 (22.0) 223 (78.0)
Knowledge of partner’s HIV status 0.636
  No 201 (43.6) 47 (24.2) 147 (75.8)
  Yes 260 (56.4) 66 (26.2) 186 (73.8)
Serodiscordant partner 0.777
  No 336 (72.9) 84 (25.7) 243 (74.3)
  Yes 125 (27.1) 29 (24.4) 90 (75.6)
Type of health centre <0.001
  Private 176 (38.2) 27 (15.7) 145 (84.3)
  Public 285 (61.8) 86 (31.4) 188 (68.6)
Availability of doctor in the centre 0.307
  No 63 (13.7) 12 (20.0) 48 (80.0)
  Yes 398 (86.3) 101 (26.2) 285 (73.8)
Number of medical assistants in the centre 0.307
  1–2 63 (13.7) 12 (20.0) 48 (80.0)
  3 and more 398 (86.3) 101 (26.2) 285 (73.8)
Number of nurses in the centre <0.001
  1–10 176 (38.2) 27 (15.7) 145 (84.3)
  11–20 57 (12.4) 18 (33.3) 36 (66.7)
  21 and more 228 (49.4) 68 (30.9) 152 (69.1)
Presence of psychologist in the centre 0.011
  No 204 (44.3) 61 (31.3) 134 (68.7)
  Yes 257 (55.7) 52 (20.7) 199 (79.3)
Child desire 0.901
  Yes 273 (60.1) 67 (24.9) 202 (75.1)
  No 181 (39.9) 44 (25.4) 129 (74.6)
Having children 0.032
  Yes 367 (79.8) 82 (23.1) 273 (76.9)
  No 93 (20.2) 31 (34.1) 60 (65.9)
Heard about contraceptive methods
  No 15 (3.3) 
  Yes 446 (96.7)
Source of information for contraceptives
  Healthcare providers 313 (70.2)
  Media 102 (22.8)
  Friends and other 31 (7.0)
Contraceptive use
  No 113 (25.3)
  Yes 333 (74.7)
Type of contraceptives methods
  Condom 248 (74.5)
  Condom+hormonal contraceptive 56 (16.8)
  Hormonal contraceptive 28 (8.4)
  Intrauterine devices 1 (0.3)
ART, antiretroviral therapy.
Table 1 Continued 
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information as the rest of the general population, which 
is a major step towards the use of contraceptive methods.
We also found that almost three-quarters (74.7%) of 
the participants were using a contraceptive method. This 
proportion was higher than that of 19.9% reported in 
the general population in 2013 in the Demographic and 
Health Surveys (DHS) in Togo.16 This was evidenced in 
prior studies conducted in Sub-Saharan Africa,12 19 which 
reported that HIV-infected women seemed to be more 
likely to use contraceptives than HIV-negative women in 
public health facilities. This could be explained by the 
fact that HIV-infected women are frequently in contact 
with health workers and received more information on 
reproductive health during their follow-up. HIV-pos-
itive women are strongly encouraged to use contracep-
tive methods to prevent mother-to-child transmission of 
HIV. Similar results were found in South-East Nigeria 
(73.1%10) or in Ethiopia (71.0%20), where a high 
proportion of HIV-infected women used contraceptives. 
However, lower rates of contraceptive use were reported 
among HIV-positive mothers in some previous studies in 
Ethiopia (45.7%18), Uganda (45%14) or Ghana (42.6%11). 
These differences might be due to temporal and regional 
variabilities, including policy guidelines on reproduc-
tive health. In fact cultural characteristics and beliefs, 
including the perception of the value of a child in the 
community, may vary through African regions, and this 
could strongly influence the decision of using a contra-
ceptive method or not. In addition, in Togo, healthcare 
providers in HIV clinics have recently benefited from a 
programme of strengthening their skills on family plan-
ning. Non-governmental organisations have also been 
established to promote reproductive health through the 
distribution of contraceptive methods. This would have 
encouraged HIV-infected women to use these methods.
As reported in previous studies in Western Africa,9–11 
condom was the most common contraceptive method 
used by HIV-infected women in this study. Fearing possible 
pharmacokinetic interactions between hormonal contra-
ceptive and antiretroviral in people living with HIV,21 22 
healthcare providers more often advised HIV-infected 
women to avoid hormonal contraceptive method in favour 
of condoms. Condoms, in addition to being accessible 
and very effective in preventing unwanted pregnancies, 
contribute to the secondary prevention of HIV, especially 
in this context where more than four out of ten HIV-in-
fected women did not know the HIV serostatus of their 
sexual partner. It is therefore important to know the influ-
ence of the HIV-infected woman in the decision-making 
process of condom use or not in a couple.
In this study, the decision to use contraceptive methods 
in HIV-infected women was influenced by several 
factors, including education level, marital status, AIDS 
clinical stage, type of health centre and having children.
Our findings revealed that women who attended school 
regardless of level (primary, secondary or higher educa-
tion) were more likely to use contraceptives than those 
who could not read and write. Women education, which 
Table 2 Factors associated with contraceptive use among 
461 HIV-infected women in the Centrale and Kara regions in 
Togo
Logistic regression models
Univariate
OR (95% CI)
Multivariate
OR (95% CI)
Education level <0.001 <0.001
  No education 1 1
  Primary 1.88 (1.04 to 3.41) 1.99 (1.05 to 3.76)
  Secondary and higher 3.62 (1.95 to 6.72) 3.95 (2.03 to 7.67)
Profession 0.192
  No profession 1
  Public sector 1.02 (0.41 to 2.53)
  Private sector 1.05 (0.33 to 3.36)
  Informal sector 0.62 (0.39 to 1.00)
Marital status 0.004 0.001
  Single 1 1
  In couple 0.52 (0.33 to 0.81) 0.45 (0.28 to 0.74)
Region 0.066
  Centrale 1
  Kara 1.51 (0.97 to 2.36)
Religion of participants 0.063
  None 1
  Islam 0.79 (0.36 to 1.7)
  Christianism 1.36 (0.64 to 2.89)
WHO clinical stage <0.001 0.101
  Stage I 1 1
  Stage II 0.51 (0.31 to 0.85) 0.7 (0.37 to 1.33)
  Stages III and IV 0.31 (0.18 to 0.54) 0.47 (0.24 to 0.94)
ART scheme 0.175
  First line 0.51 (0.19 to 1.35)
  Second line 1
Type of health centre <0.001 0.013
  Public 1 1
  Private 2.46 (1.52 to 3.98) 2.54 (1.22 to 5.29)
Number of nurses in the 
centre
0.001
  1–10 1
  11–20 0.37 (0.19 to 0.75)
  21 and more 0.42 (0.25 to 0.69)
Presence of psychologist in 
the centre
0.011
  No 1
  Yes 1.74 (1.13 to 2.69)
Having children 0.033 0.004
  No 1 1
  Yes 1.72 (1.04 to 2.83) 2.51 (1.41 to 4.5)
WHO clinical stage*type of 
health centre†
0.041
  Stage I*public centre 1
  Stage II*private centre 0.54 (0.16 to 1.81)
  Stages III and IV*private 
centre
0.13 (0.03 to 0.64)
ART, antiretroviral therapy. 
*WHO clinical stage.
†Type of health center.
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is key to societal development, remains a strong determi-
nant of contraceptive use in Sub-Saharan African. This 
result was consistent with different studies conducted 
in Ethiopia23 24 and in Malawi.25 Women who attended 
school were able to better analyse reproductive health 
information, and to understand the mechanisms of 
action, and the advantages and disadvantages of different 
contraceptive methods. This could reassure them about 
the use of these methods and allow them to make a judi-
cious choice.
Our study showed that HIV-infected women who were 
living with a partner at the time of the survey were less 
likely to use contraceptive methods. In fact women in 
couple were more likely to express their desire to have 
children. This desire is increased by social pressure, 
which underlines a great importance of having children 
in the well-being of the couple. In addition, unmarried 
women would use contraceptive methods more than 
married women to avoid unwanted pregnancies, which 
could deteriorate their social image. Unlike our finding, 
Worke et al24 in Ethiopia reported that married women 
were more likely to use contraceptives than those who 
were divorced or separated.
In our study, HIV-infected women followed up in private 
centres were more likely to use a contraceptive method. 
Although very few studies compared the quality of health-
care between the public and private sectors, particularly in 
family planning services delivery, it is generally evidenced 
that healthcare is better in private health centres.26 27 In 
private centres, even though they are non-profit-making 
facilities, it is reported that care providers are motivated 
to maximise patients’ satisfaction in order to retain them, 
and this through the provision of good-quality health-
care. However, prior studies28 29 reported that public 
health facilities were more likely to offer family planning 
services. Therefore, it is important to improve the quality 
of family planning counselling and services delivery in 
public health facilities in order to encourage patients, 
including HIV-infected women, to use these services.
Among HIV-infected women, we found that the odds of 
contraceptive use were lowest at high AIDS clinical stage. 
Indeed patients at stages III and IV were less likely to use 
contraceptive methods. At these stages of the disease, 
patients were likely to suffer from opportunistic infec-
tions with certainly a reduction of sexual activities. This 
could impact on their demand for reproductive health 
services, including contraceptive use. Moreover, the odds 
of using contraceptives are even lower when women are 
followed up in a private centre. This could be explained 
by the fact that in our setting, HIV-infected patients in the 
advanced stage of the disease are most often referred for 
treatment in public hospitals.
HIV-infected women who had children, regardless of 
number, were more likely to use a contraceptive method. 
This result is consistent with prior studies conducted in 
Uganda,30 Malawi25 and Ethiopia,23 31 which reported 
that contraceptive use increased with the number of 
children. In fact, among women who gave birth at least 
once, it is very common for them to use contraceptive 
methods to space or limit births, especially for those 
who have already reached the number of children they 
want.
limitations
First, the sample may not be representative of the 
whole country because of cultural disparities across the 
country. Second, this study took place in health facili-
ties with little chance of including patients who are less 
regular in the health centres and may have different 
characteristics. Sexually active women were defined as 
those engaging in sexual activity in the past 6 months; 
this definition used in the study could differ from 
other similar studies. In addition, we lacked informa-
tion/analysis by contraceptive types, which can impact 
mother-to-child transmission. Finally, we relied on 
self-reported reproductive health behaviour through 
a face-to-face interview, which may introduce informa-
tion bias. However, these biases would have had very 
negligible effects on the estimates in this study.
ConClusIon
This study demonstrated a high prevalence of contra-
ceptive use among HIV-infected women followed up in 
health facilities in Centrale and Kara regions in Togo. 
Private health facilities seemed to favour the use of 
contraceptive methods, but not in women at clinical 
stages III and IV. Despite these results, there is a need 
for an intensified effort to increase the reproductive 
health service utilisation particularly in public health 
facilities in these regions. HIV caregivers must also 
integrate family planning services in HIV care during 
follow-up visits.
Author affiliations
1Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales 
de la Santé & Traitement de l’Information Médicale, Marseille, France
2ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d’Azur, 
Marseille, France
3Service de maladies infectieuses, CHU Sylvanus Olympio, Université de Lomé, 
Lomé, Togo
4World Health Organization, Country Office of Togo, Lomé, Togo
5Service de médecine générale, CHR Tomdè, Kara, Togo
6Service de gynécologie-obstétrique, Clinique Biasa, Lomé, Togo
7Gynécologie-obstétrique, Évaluation de programmes, Québec, Canada
8Division de la Santé Communautaire, Ministère de la Santé, Lomé, Togo
9Service de médecine interne, CHU, Kara, Togo
10Département de Sante Publique, Université de Lomé, Lomé, Togo
11Centre Africain de Recherche en Epidémiologie et en Santé Publique, Lomé, Togo
12Service de dermatologie, CHU Sylvanus Olympio, Lomé, Togo
Acknowledgements We would like to thank the health workers involved in 
data collection for their contribution. We acknowledge all patients who agreed to 
participate in this study.
Contributors IY was responsible for the conception of the study, participated in 
the study design, undertook the field study, conducted the data collection, analysis 
and interpretation, and wrote the manuscript. AAP and DEL were involved in data 
collection, analysis and interpretation. They wrote and finalised the manuscript. 
EMB, KK, A-DDN, PMP and LD were involved in data analysis and interpretation. 
They have revised and finalised the manuscript. DKE and BS were responsible for 
 o
n
 D
ecem
ber 11, 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019006 on 24 April 2018. Downloaded from 
8 Yaya I, et al. BMJ Open 2018;8:e019006. doi:10.1136/bmjopen-2017-019006
Open Access 
the overall scientific management of the study, for analysis and interpretation, and 
the preparation of the final manuscript. All the authors read and approved the final 
manuscript to be submitted for publication.
Funding This research received no specific grant from any funding agency in the 
public, commercial or not-for-profit sectors.
Disclaimer DEL works for the WHO, Togo Country Office. The authors are solely 
responsible for the views expressed in this manuscript and do not necessarily 
represent the decisions, policies or views of the WHO.
Competing interests None declared.
Patient consent Obtained.
ethics approval This study was approved by the National AIDS and STI 
Programme of Togo (Ref N° 098/2016/MS/DSSP/PNLS-IST). 
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All data from this study can be accessed and obtained 
through the corresponding author on request.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
reFerenCes
 1. World Health Oraganiation. HIV/AIDS. Geneva, 2016.
 2. UNAIDS. AIDS by the numbers. Geneva, 2016.
 3. Reynolds HW, Janowitz B, Wilcher R, et al. Contraception to prevent 
HIV-positive births: current contribution and potential cost savings in 
PEPFAR countries. Sex Transm Infect 2008;84(Suppl 2):ii49–ii53.
 4. Crankshaw TL, Smit JA, Beksinska ME. Placing contraception 
at the centre of the HIV prevention agenda. Afr J AIDS Res 
2016;15:157–62.
 5. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in 
preventing sexually transmitted infections. Bull World Health Organ 
2004;82:454–61.
 6. WHO, USAID, FHI. Strategic considerations for strengthening the 
linkages between family planning and HIV/AIDS policies, programs, 
and services. Geneva, 2009.
 7. Wilcher R, Cates W. Reproductive choices for women with HIV. Bull 
World Health Organ 2009;87:833–9.
 8. Maier M, Andia I, Emenyonu N, et al. Antiretroviral therapy is 
associated with increased fertility desire, but not pregnancy or live 
birth, among HIV+ women in an early HIV treatment program in rural 
Uganda. AIDS Behav 2009;13(Suppl 1):28–37.
 9. Ogbe AE, Mutihir JT. Pattern of contraception among HIV 
positive women in Jos University Teaching Hospital. Niger J Med 
2012;21:11–15.
 10. Ezugwu EC, Nkwo PO, Agu PU, et al. Contraceptive use among HIV-
positive women in Enugu, southeast Nigeria. Int J Gynaecol Obstet 
2014;126:14–17.
 11. Laryea DO, Amoako YA, Spangenberg K, et al. Contraceptive use 
and unmet need for family planning among HIV positive women 
on antiretroviral therapy in Kumasi, Ghana. BMC Womens Health 
2014;14:126.
 12. Kimani J, Warren C, Abuya T, et al. Family planning use and fertility 
desires among women living with HIV in Kenya. BMC Public Health 
2015;15:909.
 13. Lawani LO, Onyebuchi AK, Iyoke CA. Dual method use for protection 
of pregnancy and disease prevention among HIV-infected women in 
South East Nigeria. BMC Womens Health 2014;14:39.
 14. Nieves CI, Kaida A, Seage GR, et al. The influence of partnership 
on contraceptive use among HIV-infected women accessing 
antiretroviral therapy in rural Uganda. Contraception 2015;92:152–9.
 15. ONUSIDA Togo. Estimations VIH et SIDA 2015. Lome, 2015.
 16. Ministère de la Planification du Développement et de l’Aménagement 
du Territoire (MPDAT), Ministère de la Santé (MS), ICF International. 
Enquête Démographique et de Santé au Togo 2013 - 2014. Rockville, 
Maryland, USA, 2015.
 17. Programme National de Lutte contre le Sida et le IST au Togo PNLS-
IST. Rapport annuel d'activités. PNLS - Togo: Lomé, 2015.
 18. Abeje G, Motbaynor A. Demand for family planning among HIV 
positive women on ART: the case of South Gondar and North Wollo 
Zones Amhara region. BMC Res Notes 2016;9:43.
 19. Bankole A, Biddlecom AE, Dzekedzeke K. Women's and men's 
fertility preferences and contraceptive behaviors by HIV status in 10 
sub-Saharan African countries. AIDS Educ Prev 2011;23:313–28.
 20. Asfaw HM, Gashe FE. Contraceptive use and method preference 
among HIV positive women in Addis Ababa, Ethiopia: a cross 
sectional survey. BMC Public Health 2014;14:566.
 21. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction 
between nevirapine and ethinyl estradiol/norethindrone when 
administered concurrently to HIV-infected women. J Acquir Immune 
Defic Syndr 2002;29:471–7.
 22. Carten ML, Kiser JJ, Kwara A, et al. Pharmacokinetic interactions 
between the hormonal emergency contraception, levonorgestrel 
(Plan B), and Efavirenz. Infect Dis Obstet Gynecol 2012;2012:1–4.
 23. Melaku YA, Zeleke EG. Contraceptive utilization and associated 
factors among HIV positive women on chronic follow up care in 
Tigray Region, Northern Ethiopia: a cross sectional study. PLoS One 
2014;9:e94682.
 24. Worke MD, Bezabih LM, Woldetasdik MA. Utilization of contraception 
among sexually active HIV positive women attending art clinic in 
University of Gondar Hospital: a hospital based cross-sectional 
study. BMC Womens Health 2016;16:67.
 25. Habte D, Namasasu J. Family planning use among women living 
with HIV: knowing HIV positive status helps - results from a national 
survey. Reprod Health 2015;12:41.
 26. Agha S, Do M. The quality of family planning services and client 
satisfaction in the public and private sectors in Kenya. Int J Qual 
Health Care 2009;21:87–96.
 27. Hutchinson PL, Do M, Agha S. Measuring client satisfaction and the 
quality of family planning services: a comparative analysis of public 
and private health facilities in Tanzania, Kenya and Ghana. BMC 
Health Serv Res 2011;11:203.
 28. Kakoko DC, Ketting E, Kamazima SR, et al. Provision of family 
planning services in Tanzania: a comparative analysis of public and 
private facilities. Afr J Reprod Health 2012;16:140–8.
 29. Barden-O'Fallon J. Availability of family planning services and 
quality of counseling by faith-based organizations: a three country 
comparative analysis. Reprod Health 2017;14:57.
 30. Muyindike W, Fatch R, Steinfield R, et al. Contraceptive use 
and associated factors among women enrolling into HIV care in 
southwestern Uganda. Infect Dis Obstet Gynecol 2012;2012:1–9.
 31. Polisi A, Gebrehanna E, Tesfaye G, et al. Modern contraceptive 
utilization among female ART attendees in health facilities of Gimbie 
town, West Ethiopia. Reprod Health 2014;11:30.
 o
n
 D
ecem
ber 11, 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019006 on 24 April 2018. Downloaded from 
